Unique ID issued by UMIN | UMIN000028601 |
---|---|
Receipt number | R000032735 |
Scientific Title | Safety and efficacy of intra-articular injection of platelet rich plasma in patients with ankle osteoarthritis |
Date of disclosure of the study information | 2017/08/10 |
Last modified on | 2017/08/09 14:51:17 |
Safety and efficacy of intra-articular injection of platelet rich plasma in patients with ankle osteoarthritis
Platelet-rich Plasma in patients with ankle osteoarthritis
Safety and efficacy of intra-articular injection of platelet rich plasma in patients with ankle osteoarthritis
Platelet-rich Plasma in patients with ankle osteoarthritis
Japan |
Ankle osteoarthritis
Orthopedics |
Others
NO
To clarify the safety and efficacy of intra-articular injection of platelet-rich plasma in patients with ankle osteoarthritis
Safety,Efficacy
Adverse events, including infection, local swelling, and redness after injection and the follow-up visits at 4, 12, 24 weeks after the last injection
Clinical evaluations (visual analogue scale for pain, JSSF scale, SAFE-Q) at 1 week before the first injection and at 4, 12, and 24 weeks after the last injection.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Maneuver |
Intra-articular injection of platelet-rich plasma into the ankle joint
2 ml per injection
3 injections with 2-week intervals.
20 | years-old | <= |
80 | years-old | >= |
Male and Female
1 Age of 20-80 years
2 Ankle pain for more than 6 months
3 Radiological diagnosis of ankle osteoarthritis
4 Not responsive to conservative treatment for at least 6 months
5 Pain visual analogue scale of 4 or more
6 Informed consent provided
1 Anemia (hemoglobin levels less than 11mg/dl)
2 Thrombocytopenia (platelet levels less than 150*103/ul)
3 History of ankle surgery or ankle fracture within the past 12 months
4 Treatment with steroid or hyaluronic acid injections within the past 6 months
5 Treatment with oral anticoagulant
6 Systemic inflammatory disease (eg rheumatoid arthritis)
7 Renal failure
8 Hepatic failure
9 Diabetes mellitus (HbA1c more than 9.0)
10 Psychological disease
11 Pregnancy
12 Infection of the ankle
13 Cancer or malignant lesions
20
1st name | |
Middle name | |
Last name | Takahisa Sasho |
Graduate School of Medicine, Chiba University
Department of Orthopaedic Surgery
1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
043-226-2117
sasho@faculty.chiba-u.jp
1st name | |
Middle name | |
Last name | Satoshi Yamaguchi |
Graduate School of Medicine, Chiba University
Department of Orthopaedic Surgery
1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
043-226-2117
y-satoshi@faculty.chiba-u.jp
Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University
Chiba Foundation for Health Promotion & Disease Prevention
Non profit foundation
NO
2017 | Year | 08 | Month | 10 | Day |
Published
No serious adverse effects were observed related with intra-articular injection of platelet rich plasma. The VAS scores significantly decreased from baseline to 4, 12, and 24 weeks after treatment. The JSSF scale score and the pain and pain-related subscale score of the SAFE-Q significantly improved from baseline to 12 weeks after treatment.
Completed
2013 | Year | 04 | Month | 09 | Day |
2013 | Year | 06 | Month | 25 | Day |
2015 | Year | 06 | Month | 26 | Day |
2015 | Year | 06 | Month | 30 | Day |
2016 | Year | 06 | Month | 30 | Day |
2016 | Year | 09 | Month | 19 | Day |
2017 | Year | 08 | Month | 09 | Day |
2017 | Year | 08 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032735